Artivion, Inc. (NYSE:AORT) SVP Jean F. Holloway Sells 5,335 Shares

Artivion, Inc. (NYSE:AORT) SVP Jean F. Holloway sold 5,335 shares of the stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $145,698.85. Following the completion of the transaction, the senior vice president now owns 149,799 shares of the company’s stock, valued at $4,091,010.69. This trade represents a 3.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Artivion Trading Down 0.2 %

Shares of AORT opened at $25.38 on Friday. Artivion, Inc. has a 1-year low of $18.38 and a 1-year high of $32.33. The business’s 50-day moving average price is $29.63 and its 200 day moving average price is $27.81. The stock has a market capitalization of $1.06 billion, a P/E ratio of -1,268.85 and a beta of 1.75. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71.

Artivion (NYSE:AORT) last announced its earnings results on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The firm had revenue of $97.31 million for the quarter, compared to analyst estimates of $100.82 million. Analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on AORT shares. Needham & Company LLC lowered their price target on Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday. Stifel Nicolaus dropped their price target on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research report on Tuesday. JMP Securities reaffirmed a “market outperform” rating and issued a $33.00 price objective on shares of Artivion in a research note on Tuesday, December 10th. Finally, Oppenheimer increased their target price on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $31.40.

Hedge Funds Weigh In On Artivion

Institutional investors and hedge funds have recently bought and sold shares of the business. Smartleaf Asset Management LLC increased its position in Artivion by 236.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock worth $32,000 after purchasing an additional 786 shares during the last quarter. Quarry LP increased its stake in shares of Artivion by 210.8% during the 3rd quarter. Quarry LP now owns 1,209 shares of the company’s stock worth $32,000 after purchasing an additional 820 shares during the last quarter. R Squared Ltd bought a new position in shares of Artivion during the 4th quarter valued at $39,000. Arcadia Investment Management Corp MI acquired a new stake in shares of Artivion in the 4th quarter valued at $43,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Artivion in the fourth quarter worth $64,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.